Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells

Haematologica

Volumn 90, Issue 10, 2005, Pages 1433-1434

  Hipp, Susanne ^a   Ringshausen, Ingo ^a   Oelsner, Madlene ^a   Bogner, Christian ^a   Peschel, Christian ^a   Decker, Thomas ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Schwerpunktpraxis für Tumortherapie   (Germany)

Author keywords

Cyclin D 1; Cyclin D3; MCL; RAD001; Rapamycin

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MITOSIS INHIBITION; PROTEIN EXPRESSION; WESTERN BLOTTING;

CELL CYCLE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEIN KINASES; SIROLIMUS;

EID: 27144455334     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive or progression-free survival. J Clin Oncol 2002;20:1288-94.
2. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998;16:13-8.
3. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol 2004;124:130-40.
4. Bjornsti MA, Houghton PJ. The tor pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
5. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-85.
6. Boffa DJ, Luan F, Thomas D, Yang H, Sharma VK, Lagman M, et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004; 10:293-300.
7. Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Hacker G, et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol 2003;122:260-8.
8. Hleb M, Murphy S, Wagner EF, Hanna NN, Sharma N, Park J, et al. Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 2004;279:31948-55.
9. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolismus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolismus European Renal Transplant Study Group. Transplantation 1999;67:1036-42.
10. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003;3:371-7.
11. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-56.